Imported a patented wound healing technology from the U.S. in collaboration with Shanghai Centre of Research and Development of New Drugs (SCOND).

Provided consulting services to the pharmaceutical giant Merck & Co. assisting in its business development activities in China.

Ongoing collaboration with Zhongxi Pharma. and Xianju Pharma. to develop ZXH951, a patented Class I new drug. Clinical trials shall begin shortly.

After several years of efforts, successfully obtained regulatory approval from the U.S. Environment Protection Agency (EPA) to market a China-produced fungicide.•

Jointly established Shanghai GeneCore with two U.S. companies, Applied

Biosystems and Celera Genomics, to conducted genomics research and development in China and achieved major breakthroughs.

Joined several venture capital firms to set up Ancile Pharmaceuticals, whose primary focus is to develop botanical drugs, of which three have been approved by the FDA to perform multi-center clinical trials.

Together with Shanghai East Best International (Group) Co., Ltd. and Shanghai Pharmaceutical (Group) Co. Ltd., established Shanghai East Best which has made significant progresses in new drug development.

Established in Shanghai the world-class laboratories that integrate synthetic, analytical, combinatorial and natural product chemistries.

Successfully carried out multilateral collaborations in Asia (with Korea, Singapore and Hong Kong); obtained phase II clinical trial approval in China, on behalf of U.S.-based FeRx, using MTC-DOX to treat liver cancer.